Oragenics to Discuss Promising Concussion Treatment in Upcoming Webinar
Biotechnology company Oragenics will host a management webinar to highlight its lead intranasal therapy ONP-002, currently in Phase IIa trials for mild traumatic brain injury, potentially addressing an unmet medical need in concussion treatment.
Oragenics Inc. will host a management webinar on May 20, 2025, to provide insights into its concussion drug program, focusing on the potential breakthrough treatment ONP-002. The intranasal therapeutic candidate is currently undergoing Phase IIa clinical trials for mild traumatic brain injury (mTBI).
The webinar will feature key leadership, including CEO Janet Huffman, Chief Medical Officer Dr. James Kelly, and Chief Clinical Officer Dr. Frank Peacock, a nationally recognized emergency medicine expert. They will discuss the unmet medical need in concussion treatment and share preliminary findings from preclinical research.
ONP-002 has shown promising early results in reducing brain inflammation and swelling, potentially offering a novel approach to treating concussions. The intranasal delivery method represents an innovative strategy for addressing neurological trauma, which could significantly impact treatment protocols for mild traumatic brain injuries.
The webinar presents an opportunity for investors, healthcare professionals, and researchers to gain deeper understanding of Oragenics' emerging neurological therapeutic approach and its potential implications for concussion management.